cigna and glp 1 coverage MCT2D Cigna dropping GLP-1 obesity drug

This landmark study of over 17,000 adults with established cardiovascular disease and overweight or obesity without diabetes demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg compared to placebo

If youre serious about optimizing your weight loss or metabolic health journey, this pack provides a well-rounded, practical approach to staying on track

and research support from Biogen, MSD, Takeda, and Pfizer

Most GLP-1 medications are administered via subcutaneous injection weekly (semaglutide, dulaglutide, exenatide extended-release) or daily (liraglutide), with oral semaglutide (Rybelsus) representing the only currently available oral formulation